City of Hope shared a post on LinkedIn:
“City of Hope has opened an innovative Phase 2 clinical trial designed to map how tumors change as they begin to resist immunotherapy, treatment that improves the immune system’s ability to fight disease. The research focuses on advanced non-small cell lung cancer, the most common type of lung cancer, accounting for 87% of cases.
Aiming to enroll 535 patients newly diagnosed with NSCLC, the six-year IMMUNO-BIOMAP trial will use predictive models to tailor treatments to the evolving biology of patients’ tumors. Doctors often rely on immune checkpoint inhibitors to treat advanced NSCLC, but fewer than 40% of patients see positive results, and many develop resistance to the drugs.
The trial will run across select City of Hope locations across the nation. City of Hope’s national clinical trials model is a fully integrated network of 39 sites in four states, structured for faster trial activation and consistent execution across locations. An award of up to $23.7 million from the Advanced Research Projects Agency for Health (ARPA-H) funds the research, and City of Hope is the only institution in the nation to receive ARPA-H funding for lung cancer research in the ADAPT study.
‘Our goal is to create clear guidelines for selecting the best next treatment when a patient’s cancer doesn’t respond to initial therapy. City of Hope is determined to find a reliable way to predict who will benefit from immunotherapy and who might experience better results with other treatment options.'”
